Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Gastroenterology
Clinical Trials: Stomach Cancer
A listing of clinical trials currently looking for volunteers to enroll in Stomach Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Alaska
Arizona
California
Beverly HIlls : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Beverly HIlls : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Duarte : City of Hope Updated
A Random Assignment Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouacil (mDCF) versus Parent DCF with Growth Factor Support in Patients with Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
Duarte : City of Hope Updated
Quality of Life in Patients Undergoing Laparoscopic Distal Gastrectomy with Billroth II Reconstruction at the City of Hope
View More »
Alhambra : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Bakersfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Fullerton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Los Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Redondo Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Barbara : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Maria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Santa Monica : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Stanford : Stanford University School of Medicine
Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Colorado
Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Grand Junction : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Florida
Englewood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Pembroke Pines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
West Palm Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Georgia
Indiana
Iowa
Kansas
Louisiana
Maine
Maryland
Massachusetts
Burlington : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Springfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Michigan
Ann Arbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Detroit : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kalamazoo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Minnesota
Duluth : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
St Louis Park : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Missouri
Montana
Billings : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Bozeman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Nebraska
Nevada
New Jersey
New Mexico
Albuquerque : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Albuquerque : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
New York
Ohio
Cincinnati : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Dayton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Oklahoma
Pennsylvania
Hershey : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
View More »
Danville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Dunmore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
South Carolina
Charleston : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Charleston : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
View More »
Charleston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Spartanburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Tennessee
Chattanooga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Nashville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Texas
Dallas : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Houston : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Adenocarcinoma Of The Stomach
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Small Intestine
Utah
Virginia
Washington
Bellevue : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Kirkland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Mount Vernon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Port Angeles : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
View More »
Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Wenatchee : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Wisconsin
Madison : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Marshfield : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
A Study of Ramucirumab in Patients With Gastric, Esophageal and Gastroesophageal Cancer
Argentina
Rosario : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Belgium
Bruxelles : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Edegem : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Gent : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Liège : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Brazil
Porto Alegre : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Salvador : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
São Paulo : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
São Paulo : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Bulgaria
Gabrovo : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pleven : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Varna : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Vratsa : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Colombia
Teusaquillo : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Croatia
Osijek : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Zagreb : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Estonia
Tallinn : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Germany
Aachen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Essen : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Herne, NRW : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Leverkusen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Muenchen : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Trier, RP : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Hungary
Budapest : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Gyor : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Nyíregyháza : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pécs : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Szeged : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Székesfehérvár : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Israel
Beer Sheva : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Jerusalem : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kfar Saba : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Ramat Gan : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Tel Aviv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Italy
Milano : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Milano : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Modena : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Potenza : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Reggio Emilia : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Rimini : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Mexico
Chihuahua : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Poland
Gdansk : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lodz : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Olsztyn : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Szczecin : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Warszawa : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Portugal
Aveiro : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Coimbra : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Porto : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Romania
Baia Mare : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Cluj-Napoca : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Iasi : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Onesti : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Russia
Barnaul : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Moscow : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Saint Petersburg : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Saint Petersburg : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
South Africa
Durban : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Groenkloof Pretoria : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Port Elisabeth : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Pretoria : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Spain
Barcelona : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Barcelona : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Elche : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Madrid : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Malaga : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Sabadell : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Valencia : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Ukraine
Cherkassy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Chernivtsiy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Dnepropetrovsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Donetsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kharkiv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Kyiv : Research Site
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lutsk : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Lviv : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Sumy : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Uzhgorod : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Zaporizzhya : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
United Kingdom
London : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
Rhyl : Research Center
Diffuse Gastric and Esophagogastric junction cancer S-1 Trial
United States
